This HTML5 document contains 56 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
n20http://linked.opendata.cz/resource/drugbank/drug/DB06694/identifier/wikipedia/
dctermshttp://purl.org/dc/terms/
n26http://linked.opendata.cz/resource/AHFS/
n19http://linked.opendata.cz/resource/drugbank/drug/DB06694/identifier/pharmgkb/
n24http://linked.opendata.cz/resource/mesh/concept/
foafhttp://xmlns.com/foaf/0.1/
n12http://linked.opendata.cz/resource/drugbank/drug/DB06694/identifier/kegg-compound/
n17http://linked.opendata.cz/resource/drugbank/drug/DB06694/identifier/bindingdb/
n8http://linked.opendata.cz/resource/drugbank/drug/DB06694/identifier/pubchem-compound/
n9http://linked.opendata.cz/resource/drugbank/drug/DB06694/identifier/pubchem-substance/
n14http://bio2rdf.org/drugbank:
n15http://linked.opendata.cz/resource/drugbank/drug/DB06694/identifier/drugbank/
n11http://linked.opendata.cz/resource/drugbank/drug/DB06694/identifier/iuphar/
admshttp://www.w3.org/ns/adms#
n16http://linked.opendata.cz/resource/drugbank/drug/DB06694/identifier/guide-to-pharmacology/
n25http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n23http://linked.opendata.cz/ontology/mesh/
n3http://linked.opendata.cz/ontology/drugbank/
n18http://linked.opendata.cz/resource/drugbank/drug/DB06694/identifier/chemspider/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n22http://nosesprays.info/
n6http://linked.opendata.cz/resource/atc/
n5http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB06694
rdf:type
n3:Drug
n3:description
A nasal vasoconstricting decongestant drug which acts by binding to the same receptors as adrenaline. It is applied as a spray or as drops into the nose to ease inflammation and congestion of the nasal passageways. It binds alpha-adrenergic receptors to activate the adrenal system which causes systemic vasoconstriction, thereby easing nasal congestion.
n3:generalReferences
# Haenisch B, Walstab J, Herberhold S, Bootz F, Tschaikin M, Ramseger R, Bonisch H: Alpha-adrenoceptor agonistic activity of oxymetazoline and xylometazoline. Fundam Clin Pharmacol. 2009 Dec 17. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/20030735
n3:group
approved
n3:indication
It is used for treating nasal congestion and minor inflammation due to allergies or colds.
owl:sameAs
n14:DB06694 n25:DB06694
dcterms:title
Xylometazoline
adms:identifier
n8:5709 n9:99443248 n11:517 n12:C07913 n15:DB06694 n16:517 n17:50027068 n18:5507 n19:PA165958368 n20:Xylometazoline
n3:mechanismOfAction
Xylometazoline is a direct acting sympathomimetic drug, which acts on alpha-adrenergic receptors in the arterioles of the nasal mucosa. This activates the adrenal system to yield systemic vasoconstrction. In producing vasoconstriction, the result is a decrease in blood flow in the nasal passages and consequently decreased nasal congestion.
n3:synonym
Xylomethazoline Balminil
n5:hasAHFSCode
n26:52-32-00
n23:hasConcept
n24:M0054607
foaf:page
n22:result.php?Keywords=Nasal%20Spray
n3:IUPAC-Name
n4:271B4E93-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B4E99-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B4E98-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B4E95-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B4E96-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B4E97-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B4E91-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B4EA9-363D-11E5-9242-09173F13E4C5 n4:271B4E8F-363D-11E5-9242-09173F13E4C5 n4:271B4E92-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B4E90-363D-11E5-9242-09173F13E4C5
n5:hasATCCode
n6:R01AB06 n6:S01GA03 n6:R01AA07
n3:H-Bond-Acceptor-Count
n4:271B4E9F-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B4EA0-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B4E9A-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B4E9B-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B4E9D-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B4E9C-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B4E9E-363D-11E5-9242-09173F13E4C5
n3:casRegistryNumber
526-36-3
n3:category
n3:Bioavailability
n4:271B4EA4-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B4EA6-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B4EA7-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B4EA8-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B4EA3-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B4EA2-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B4EA5-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B4E94-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B4EA1-363D-11E5-9242-09173F13E4C5